Social Security and Medicare spending could double by 2023; FDA panel experts want naloxone to be available over the counter after the drug information is revised; Moderna announced its COVID-19 vaccines will stay free, and the Biden administration might keep tests and treatments free for the uninsured.
The Congressional Budget Office (CBO) said Wednesday that spending on Medicare and Social Security is projected to double by 2033, due to the increasing cost of medical services and a growing number of eligible beneficiaries, reported The Hill. In another report, the CBO said this week that Social Security trust funds are expected to start running short in 2032, a year earlier than it predicted in December.
A panel of outside FDA experts unanimously voted on Wednesday that the overdose-reversing drug naloxone should be offered over the counter to help fight the national opioid crisis, according to the Associated Press. The FDA may or may not follow the panel’s recommendation. The manufacturer said it would revise the label and packaging in response to concerns from panel members, who noted a study that said some people found the drug’s instructions confusing. A final decision by the FDA is expected in the coming weeks.
Moderna announced that people who are insured will be able to get a free COVID-19 vaccine from their doctor’s office or a pharmacy, and uninsured people or those whose insurance won’t cover the vaccine can get it for free through Moderna’s patient assistance program, reported CBS Boston. This announcement comes after The Wall Street Journal reported in January that Moderna was thinking of charging $110 to $130 per vaccine dose. Additionally, Politico reported that the Biden administration is considering keeping COVID-19 tests and treatments free for the uninsured into 2024 despite the public health emergency’s end in May.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
2 Commerce Drive
Cranbury, NJ 08512